Investor Flagship Ventures Fund IV General Partner LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Flagship Ventures Fund IV General Partner LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2022-02-14 13G/A MRNA / Moderna, Inc. 33,143,511 20,008,540
2022-02-14 13G/A RUBY / Rubius Therapeutics, Inc. 38,340,276 38,581,526
2021-02-16 13G/A MRNA / Moderna, Inc. 51,008,692 33,143,511
2021-02-16 13G/A RUBY / Rubius Therapeutics, Inc. 38,296,526 38,340,276
2020-02-13 13G/A MRNA / Moderna, Inc. 51,008,692
2019-02-13 13G RUBY / Rubius Therapeutics, Inc. 38,296,526 38,296,526
2019-02-12 13G RUBY / Rubius Therapeutics, Inc. 38,296,526
2017-08-21 13D/A SYRS / Syros Pharmaceuticals, Inc. 4,806,656 3,228,964
2016-07-11 13D SYRS / Syros Pharmaceuticals, Inc. 4,806,656